Fiche société
Immedica Pharma AB
Traitements, essais et publications liés.
Traitements3programmes
Essais2liés
Publications3liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| GanaxoloneTo assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the treatment of primary seizure types in patients with genetically- or clinically-confirmed TSC-related epilepsy through the end of the 12 week treatment period. | Épilepsie, SEP | Phase 3 | À vérifier | United States | À vérifier |
| GanaxoloneTo assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the treatment of primary seizure types in patients with genetically- or clinically-confirmed TSC-related epilepsy through the end of the 12 week treatment period. | SEP | Phase 2 | À vérifier | United States | À vérifier |
| GanaxoloneTo assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the treatment of primary seizure types in patients with genetically- or clinically-confirmed TSC-related epilepsy through the end of the 12 week treatment period. | Épilepsie | Phase 3 | À vérifier | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ganaxolone | Épilepsie | Phase 3 | NCT05249556 | Open-label, Single-arm Trial of Ganaxolone in CDD Patients 6 Months to Less Than 2 Years Old | NOT_YET_RECRUITING |
| Ganaxolone | SEP | Phase 2 | NCT04285346 | Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) | COMPLETED |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Ganaxolone | Ganaxolone, an approved therapy for CDKL5-deficiency disorder, is an inhibitor of PTP1B. | The Journal of biological chemistry | ||
| Ganaxolone | Comprehensive evaluation of neurosteroid monotherapy and neurosteroid-midazolam combination therapy in mitigating the nerve agent soman-induced chronic neuropsychiatric dysfunction, epileptogenesis, neuroinflammation and neurodegeneration in pediatric models. | Neuropharmacology | ||
| Ganaxolone | Allosteric potentiation of GABA receptor promotes survival and maturation of oligodendroglial cells in vitro via Ca/CaMK/AKT signaling pathway. | American journal of physiology. Cell physiology |